Tumor cell response to bevacizumab single agent therapy in vitro
about
Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.Obesity-related known and candidate SNP markers can significantly change affinity of TATA-binding protein for human gene promoters.Candidate SNP markers of aggressiveness-related complications and comorbidities of genetic diseases are predicted by a significant change in the affinity of TATA-binding protein for human gene promoters.Candidate SNP Markers of Gender-Biased Autoimmune Complications of Monogenic Diseases Are Predicted by a Significant Change in the Affinity of TATA-Binding Protein for Human Gene PromotersSoluble VEGF receptor 1 (sFLT1) induces non-apoptotic death in ovarian and colorectal cancer cellsCombinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer.Candidate SNP Markers of Chronopathologies Are Predicted by a Significant Change in the Affinity of TATA-Binding Protein for Human Gene Promoters.Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update.How to Use SNP_TATA_Comparator to Find a Significant Change in Gene Expression Caused by the Regulatory SNP of This Gene's Promoter via a Change in Affinity of the TATA-Binding Protein for This Promoter.Zoledronic Acid, Bevacizumab and Dexamethasone-Induced Apoptosis, Mitochondrial Oxidative Stress, and Calcium Signaling Are Decreased in Human Osteoblast-Like Cell Line by Selenium Treatment.Candidate SNP markers of reproductive potential are predicted by a significant change in the affinity of TATA-binding protein for human gene promoters.Patient derived renal cell carcinoma xenografts exhibit distinct sensitivity patterns in response to antiangiogenic therapy and constitute a suitable tool for biomarker development
P2860
Q30934034-3764F99B-05FD-4008-9710-3B75CCF67538Q35875387-913315F6-D361-4A27-A4E3-51C4BB13F89BQ36255004-009E7E93-7719-4B83-B060-F21FB2210A79Q36760451-2AB3AB3B-4D00-4169-9827-5F1433B3CB84Q36824048-E2E17CF1-F633-4416-9C8D-82B73364058BQ37045403-99B281B4-6234-474D-BC65-E1457BB66ED2Q37231785-752A0542-D146-49DD-85BF-9DA7C6C51D24Q38317180-E9DA1BF6-AA16-4FA2-A7A9-8341F70EBB08Q42179348-398F0C46-96B5-4B26-8EC7-1AE4DBC82716Q46272591-C241AF87-B71E-4BE8-9754-340C3A7E698EQ54936700-E7392387-1D1D-4F43-A1FF-E05878D826A5Q56525807-8D30A484-50CD-44A5-8C6A-AA8B7C3DA4A0
P2860
Tumor cell response to bevacizumab single agent therapy in vitro
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Tumor cell response to bevacizumab single agent therapy in vitro
@en
Tumor cell response to bevacizumab single agent therapy in vitro.
@nl
type
label
Tumor cell response to bevacizumab single agent therapy in vitro
@en
Tumor cell response to bevacizumab single agent therapy in vitro.
@nl
prefLabel
Tumor cell response to bevacizumab single agent therapy in vitro
@en
Tumor cell response to bevacizumab single agent therapy in vitro.
@nl
P2860
P356
P1476
Tumor cell response to bevacizumab single agent therapy in vitro
@en
P2093
Melanie Hein
Shannon Graver
P2860
P2888
P356
10.1186/1475-2867-13-94
P577
2013-09-23T00:00:00Z
P5875
P6179
1008953195